Background {#Sec1}
==========

Diabetes mellitus (DM) is a devastating metabolic disorder that places an economic burden for every country around the world with the global increasing trend. As a cost of urbanization, the overall status of diabetes according to IDF estimates in 2017 showed that there are now 425 million adults with diabetes and 352 million adults with impaired glucose tolerance worldwide \[[@CR1]\]. Jordan already has a high prevalence of DM and impaired fasting glucose approaching 24.9% in the year 2008 \[[@CR2]\]. The age- adjusted prevalence rates in Saudi Arabia, Kuwait, Qatar and Jordan was 17.7, 15.8, 16.5 and 11.8%, respectively \[[@CR1]\]. A great rise in diabetes prevalence is expected in Jordan due to alarming rates of obesity, economic growth, nutrition transition and a particular challenge of a large proportion of the resident population that consists of refugees and migrants from nearby countries including Syria and Iraq \[[@CR1]--[@CR3]\]. The overall prevalence of overweight and obesity among adult Jordanian was 31.4 and 51.7%, respectively \[[@CR3]\]. According to WHO estimates, the highest levels of overweight and obesity from 16 countries in the Eastern Mediterranean Region were in Egypt, Bahrain, Jordan, Kuwait, Saudi Arabia and United Arab Emirates \[[@CR4]\]. The prevalence of overweight and obesity in these countries ranged from 69 to 77% in men and 74 to 86% in women \[[@CR4]\].

Neuropathy is the most common microvascular complications among diabetics that can involve peripheral, central and/or autonomic nervous systems \[[@CR5]--[@CR7]\]. It can also develop at earlier stages of dysglycemia as in the pre-diabetic phase \[[@CR5], [@CR7]\]. Peripheral neuropathy (PN) is the predominant variety in patients with diabetes whether type 1 or type 2. It manifests as distal symmetrical polyneuropathy (DSPN), also known as diabetic peripheral neuropathy (DPN), causing nerve damage in the extremities particularly the feet, in addition to radiculopathy and mononeuropathy \[[@CR5], [@CR6]\]. Clinically, DPN is defined as the presence of symptoms or signs of peripheral nerve dysfunction in people with diabetes after other possible causes have been excluded \[[@CR8]\]. This definition reflects that the causality of neuropathy in diabetic patients is related to various factors in addition to hyperglycemia. However, the symptoms are not a reliable indicator for the presence of neuropathy in the disease course, since up to 50% of patients with neuropathy are asymptomatic; therefore, they are prone to insensate foot complications \[[@CR9], [@CR10]\]. Even in symptomatic patients, the spectrum of clinical manifestations is broad because of the complex anatomy of the peripheral, central and autonomic nervous systems.

DPN increases the risk of the foot infection, ulcers and non-traumatic amputations, eventually causing long-term disability \[[@CR9], [@CR11], [@CR12]\]. The lifetime risk for the development of foot ulcers in patients with type 2 diabetes mellitus (T2DM) is 15--25% \[[@CR9], [@CR11]\]. DPN is one of three main risk factors for the occurrence of falls among patients with diabetes, along with vestibular dysfunction and diabetic retinopathy. In fact, the risk of falls is 2--3 times more likely in patients with DPN \[[@CR13]\]. Overall, DPN has a significant impact on the quality of life, work productivity and health care resources utilization due to prolonged hospitalization \[[@CR6], [@CR14]\]. So far, the mainstay of treatment for DPN is pain management, while glycemic control is the only disease modifying therapy \[[@CR6]\]. Therefore, peripheral neuropathy is one of the cardinal aspects when counseling diabetic patients and early detection in primary care setting is necessary to initiate the appropriate interventions in order to decrease disability, limb loss and improve the quality of life.

This study was conducted to determine the prevalence of DPN among patients with T2DM attending National Center for Diabetes, Endocrinology and Genetics (NCDEG) in Jordan and identify predictors of DPN.

Methods {#Sec2}
=======

This study was cross-sectional in design conducted among adult patients (≥ 18 years) with T2DM who had regular follow up visits at the NCDEG for at least 6 months. Adult patients who underwent amputation of the whole foot, below knee and above knee amputations were excluded from the study. This study was conducted at NCDEG in Amman city, Jordan. Jordan is a small lower-middle income country with limited natural resources. Its surface area is about 89,300 square km, of which only 7.8% is arable land. Its population is about 9.8 million of whom 90.3% live in urban areas \[[@CR15]\]. Around 629,245 of Syrians' refugees are currently living in Jordan. Jordan's health care system has improved dramatically over the last two decades and is ranked as one of the best systems in the Middle East. It is a complex amalgam of three major sectors: public, private, and non for profit organizations. The NCDEG is a national and specialized referral outpatient center that deals with cases of DM from all over Jordan and mainly serving a population of 4.1 million in Amman City. The NCDEG provides its services to the majority of patients with DM in Amman city, including those with health insurance. More than 70% of Jordanians had medical insurance. In 2017, NCDEG served 116,226 patients. Usual care of patients involves regular follow up every 3 months with weight, height and blood pressure measurements, fundus and foot examinations in addition to glycated hemoglobin (HbA1c). Yearly evaluation of microvascular complication in addition to lipid profile is a routine practice in all cases of DM in our center.

The study was approved by the ethics committee at the NCDEG. Eligible patients gave written informed consent and the confidentiality of the information was assured. The questionnaire and clinical examination were pilot tested on 100 participants (not included in this study) to ensure feasibility of the study and clear understanding of the inquiries. A total of 1003 patients with T2DM were recruited from the general diabetes clinics during the period from November 2014 to February 2015.

The socio-demographic data were collected from participants using a face-to-face structured interview, which included age, gender, marital status, regular visits to the treating physician every 3 months, family history of DM, physical and working status. The patient was considered to have regular, not regular and no physical activity if the patient walked 30 min for 4--7 days, 1--3 days/week, and less than once weekly, respectively. Clinical data related to the duration of diabetes, medications, the presence of nephropathy, diabetic retinopathy, hypertension, dyslipidemia cardiovascular disease, body mass index (BMI), and HbA1c were collected from medical files. HbA1c is measured using a high-performance liquid chromatography (HPLC) method with Bio-Rad VARIANT™ II Turbo 2.0 and D 10 Analyzer (Bio-Rad Laboratories).

The diagnosis of hypertension and dyslipidemia at the NCDEG are based on American Diabetes Association (ADA) criteria \[[@CR16]\]. Nephropathy was defined as the presence of persistent albuminuria at levels 30--299 and levels ≥ 300 mg/24 h urine collection sample \[[@CR16]\]. Cardiovascular disease (CVD) was defined as a previous diagnosis of coronary artery disease (CAD) by angiography or ECG, and or current treatment for CAD. Diabetic retinopathy diagnosis was based on dilated fundus examination carried out by experienced ophthalmologists.

The Michigan Neuropathy Screening Instrument (MNSI) was used to evaluate the presence of DPN \[[@CR17]\]. Michigan Neuropathy Screening Instrument (MNSI) is a well-known instrument used to assess peripheral neuropathy among patients with T2DM with a sensitivity of 80% and a specificity of 95% \[[@CR18], [@CR19]\]. MNSI is a validated simple noninvasive and inexpensive measurement tool that incorporates sensory and motor components of neuropathy. Since its development, it became imperatively important to diagnose DPN as early as possible in order to prevent amputations, disability and improve the quality of life \[[@CR17]\]. The MNSI consists of two-steps: The first step of MNSI is the history questionnaire that assessed the presence of neuropathic symptoms. Translation of the history part of the MNSI to the Arabic language was done by the researcher and checked by three professionals in the field of neurology, endocrinology, and nursing (It was valid and reliable through pilot testing of the instrument that was carried out on 100 patients). This part consists of 15 items, (13) items assessed symptoms of DPN, item number (4) assessed peripheral vascular disease (PVD), and item number (10) assessed general asthenia. The score range from 0 to 13 points and a score that is ≥ 7 indicates the presence of neuropathic symptoms. The second step of the MNSI is the physical examination part that was carried by the researchers. It assessed the following five variables on each foot: inspection of each foot for deformities, dry skin, calluses or infections, the presence or absence of ulceration, examination of vibration sense by tuning fork 128 Hz, the presence or absence of the ankle reflex using hummer and using Semmes--Weinstein Monofilament (SWM) to test sensation of feet. The researchers were healthcare professionals, trained by a professor of neurology at a university hospital for proper physical examination of MNSI tool and supervised by an endocrinologist at the NCDEG. The patient is considered to have neuropathy if the score is equal or more than two points on a 10 points scale on the physical examination part of MNSI. DPN based on MNSI scores were present if the score is equal or more than seven in the history part or a score equal or more than two in the physical examination part or both.

Data were analyzed by using the Statistical Package for Social Sciences (SPSS, version 20). Data were described using mean values for continuous variables and proportions for categorical variables. The *t* test was used to compare the means and Chi square was used to test independent distribution of categorical variables where appropriate. Binary logistic regression was used to identify independent predictors of peripheral neuropathy after adjusting all other potential confounders. A p value less than 0.05 was considered as statistically significant in the analysis.

Results {#Sec3}
=======

Participants' characteristics {#Sec4}
-----------------------------

The study included a total of 1003 type 2 diabetic patients aged between 31 and 88 years with a mean age of 59.76 years (SD = 9.82). Their socio-demographic and clinical characteristics are shown in Table [1](#Tab1){ref-type="table"}. More than half of the participants were females, 34% were unemployed and 62.1% were physically inactive. The mean BMI of study participants were 32 kg/m^2^ (SD = 5.63). The mean duration of diabetes was 9.24 years, almost one-third of participants were having diabetes for more than 12 years and 42% were having controlled diabetes. Microvascular complications in the form of retinopathy and nephropathy were present in 19.5 and 9.4%, respectively. The majority of study subjects were having dyslipidemia and almost all patients with dyslipidemia were receiving statin therapy. Moreover, 38.2 and 85.7% were having cardiovascular disease and hypertension, respectively (Table [1](#Tab1){ref-type="table"}).Table 1Socio-demographic, clinical and laboratory data of the study participantsVariablesn(%)Age group (year) \< 5013213.2 50--6969269.0 ≥ 7017917.8Gender Male48047.9 Female52352.1Marital status Single/divorced and widowed12812.8 Married87587.2Working status Unemployed34434.3 Employed28027.9 Retired37937.8Physical activity Regular929.2 Not regular28828.7 No physical activity62362.1Family history of diabetes86986.6Regular visit to treating physician91791.4Body mass index (BMI) (kg/m^2^)^a^ Normal858.5 Over weight30230.1 Obese61661.4Duration of diabetes (year) \< 533333.2 5--1135635.5 ≥ 1231431.3Hypertension86085.7Dyslipidemia88688.3Retinopathy19619.5Nephropathy949.4Cardiovascular disease38338.2Type of treatment Insulin only12812.8 Oral hypoglycemia agents only52752.5 Oral hypoglycemia agents and insulin34834.7Statin therapy88688.3HbA1C (%) Controlled \< 7%42242.1 Uncontrolled ≥ 7%58157.9^a^Normal: 18.5--24.9, over weight: 25--29.9 and obese ≥ 30

Prevalence of DPN {#Sec5}
-----------------

The overall prevalence of DPN among study participants based on MNSI was 39.5%. Based on MNSI assessment, 16.5 and 34.8% of study participants had a score of ≥ 7 in the history questionnaire and a score of ≥ 2 in the physical examination section of the MNSI, respectively. Of those with DPN (396 patients), 88.1% had a score of ≥ 7 in the history questionnaire of the MNSI and 41.7% had a score of ≥ 2 in the physical examination section of the MNSI.

The history questionnaire of the MNSI assessment showed that most of the participants had at least one symptom of the DPN. The most frequently reported symptoms in DPN patients were numbness and pain with walking which was present in 81.8 and 75.3% of study participants, respectively while, the least reported symptoms were history of one or more toes amputation and loss of sensation in legs/feet while walking which was present in 3.3 and 9.6% of patients, respectively (Table [2](#Tab2){ref-type="table"}).Table 2Responses to Michigan neuropathy screening instrument questionnaire in patients with diabetic peripheral neuropathy (n = 396)SymptomN (%)A: History questionnaire Did your legs/feet numb?324 (81.8) Do you have burning pain in your legs/feet?294 (74.2) Are your feet too sensitive to touch?155 (39.1) Do you have prickling feelings in your legs/feet?242 (61.1) Does it hurt when the bed covers touch your legs/feet?99 (25) Can you differentiate hot water from cold water in the tub/shower?59 (14.9) Have you had open sore on your foot?85 (21.5) Has your doctor ever told you that you have neuropathy?199 (50.3) Are your symptoms worse at night?276 (69.7) Do your legs/feet hurt when you walk?298 (75.3) Are you able to sense your legs/feet when you walk?38 (9.6) Is the skin on your legs/feet so dry that it cracks open?78 (19.7) Have you had an amputation?13 (3.3)Physical examinationRight foot N (%)Left foot N (%)B: Physical assessment Abnormal appearance of feet293 (74)293 (74) Ulceration45 (11.4)44 (11.1) Ankle reflexes abnormality198 (50)203 (51) Vibration perception abnormality262 (66)262 (66) Monofilament test abnormality314 (79)310 (78)

The prevalence of DPN for study participants using MNSI according to relevant socio-demographic, clinical and laboratory characteristics is shown in Table [3](#Tab3){ref-type="table"}.Table 3Prevalence of DPN for patients with type 2 DM using MNSI according to relevant socio-demographic, clinical and laboratory characteristicsVariablesNeuropathy statusp valueWithout DPN n = 607 (100%)With DPN n = 396 (100%)Gender0.137 Male201 (41.9)279 (58.1) Female195 (37.3)328 (62.7)Age group (year): (mean ± SD)(62.7 ± 9.2)(57.8 ± 9.7)\< 0.001\* \< 5023 (17.4)109 (82.6) 50--69269 (38.9)423 (61.1) ≥ 70104 (58.1)75 (41.9)Marital status0.777 Single/divorced and widowed52 (40.6)76 (59.4) Married344 (39.3)531 (60.7)Working status\< 0.001\* Unemployed175 (50.9)169 (49.1) Employed83 (29.6)197 (70.4) Retired138 (36.4)241 (63.6)Physical activity\< 0.001\* Regular29 (31.5)63 (68.5) Not regular72 (25)216 (75) No physical activity295 (47.4)328 (52.6)Family history of diabetes0.014\* Present356 (41)513 (59) Absent40 (29.9)94 (70.1)Regular visit to treating physicians\< 0.001\* Yes342 (37.3)575 (62.7) No54 (62.8)32 (37.2)Body mass index (BMI) (kg/m^2^): (mean ± SD)(32.9 ± 6.0)(31.4 ± 5.3)0.052 Normal32 (37.6)53 (62.4) Over weight103 (34.1)199 (65.9) Obese261 (42.4)355 (57.6)Duration of diabetes (year): (mean ± SD)(14.1 ± 7.4)(6.0 ± 5.1)\< 0.001\* \< 529 (8.7)304 (91.3) 5--11139 (39)217 (61) ≥ 12288 (72.6)86 (27.4)Having hypertension\< 0.001\*SBP mmHg (mean ± SD)(142.4 ± 18.1)(138.3 ± 17.5)DBP mmHg (mean ± SD)(77.0 ± 11.3)(78.2 ± 10.1) Yes374 (43.5)486 (56.5) No22 (15.4)121 (84.6)Nephropathy\< 0.001\* Yes65 (69.1)29 (30.9) No331 (36.4)578 (63.6)Cardiovascular disease\< 0.001\* Yes210 (54.8)173 (45.2) No186 (30)434 (70)Dyslipidemia\< 0.001\* Yes381 (43)505 (57) No15 (12.8)102 (87.2)TC (mean ± SD)(178.6 ± 54)(170.9 ± 47.3)0.016LDL (mean ± SD)(101.0 ± 30.1)(102.1 ± 31.1)\< 0.001\*HDL (mean ± SD)(39.5 ± 11.3)(41.9 ± 11.5)0.001TG (mean ± SD)(177.4 ± 81.7)(160.2 ± 71.8)0.558Statin therapy381 (96.2%)505 (83.2%)\< 0.001\*Retinopathy\< 0.001\* Yes132 (67.3)64 (32.7) No264 (32.7)543 (67.3)Type of treatment\< 0.001\* Insulin only77 (60.2)51 (39.8) Oral hypoglycemia agents only120 (22.8)407 (77.2) Oral hypoglycemia agents and insulin199 (57.2)149 (42.8)HbA1C (%): (mean ± SD)(8.0% ± 1.5)(7.1% ± 1.3)\< 0.001\* Controlled \< 7%96 (22.7)326 (77.3) Uncontrolled ≥ 7%300 (51.6)281 (48.4)\* Indicates statistically significant variables using x^2^ test at α \< 0.05 level

Multivariate analysis of factors associated with DPN {#Sec6}
----------------------------------------------------

Multiple logistic regression analysis showed that unemployment, cardiovascular disease, dyslipidemia, diabetic retinopathy and duration of diabetes were significantly associated with DPN. Patients receiving oral hypoglycemic agents and having not regular physical activity were less likely to have DPN (Table [4](#Tab4){ref-type="table"}). The likelihood of DPN was higher among patients with diabetic retinopathy (OR = 2.26, 95% CI: 1.5--1.3, *p* \< *0.001*). Compared to patients who were physically inactive, patients with not regular physical activity (patients walked 30 min for 1--3 days/week) were less likely to have DPN (OR = 0.515, *p* = *0.001*). Cardiovascular disease and dyslipidemia were significantly associated with increased odds for DPN (OR = 1.43 and 2.23, respectively). Patients maintained on oral hypoglycemic agents were less likely to have DPN (OR = 0.639, *p* = 0.016) than those receiving insulin therapy in addition to oral hypoglycemic agents. Diabetes duration was the strongest predictor for DPN; compared to patients with T2DM for less than 5 years, those with diabetes duration for 5--11 years (OR = 5.25) and ≥ 12 years (OR = 16.98) were more likely to have DPN *(p* \< *0.001).*Table 4Multivariate analysis of factors associated with DPN according to MNSI in patients with type 2 DM (n = 1003)VariablesOR95% confidence interval lower--upperp valueWorking status Retired1 Unemployed1.861.27--2.730.001 Employed1.40.92--2.140.112Physical activity No physical activity1 Not-regular0.5150.35--0.750.001 Regular0.7120.40--1.250.239Cardiovascular disease No1 Yes1.431.02--2.010.037Retinopathy No1 Yes2.261.17--4.24\< 0.001Dyslipidemia No1 Yes2.231.17--4.240.014Type of treatment Oral hypoglycemia agents and insulin1 Insulin only1.170.72--1.910.509 Oral hypoglycemia agents only0.6390.44--0.920.016Duration of diabetes (year) \< 51 5--115.253.29--8.36\< 0.001 ≥ 1216.9810.19--28.28\< 0.001Hypertension No1 Yes1.060.56--2.010.839HbA1C (%) Controlled \< 7%1 Uncontrolled ≥ 7%1.310.91--1.890.144Body mass index (BMI) (kg/m^2^) Normal1 Over weight0.7760.42--1.430.418 Obese0.8160.45--1.460.4931 Reference group

Discussion {#Sec7}
==========

The current study intended to determine the prevalence of DPN and its correlates in patients with T2DM. The overall prevalence of DPN was 39.5%. There was no difference according to gender. Based on patients' responses to MNSI: 41.9% of males were having DPN and 37.3% of females were having DPN (*p* = 0.137).

The results are consistent with several recent studies from Middle East countries in which the prevalence of DPN was 45, 31.9, 25.6 and 29.2% in Saudi Arabia, Iran, United Arab Emirates (UAE) and India, respectively \[[@CR20]--[@CR23]\] (shown in Table [5](#Tab5){ref-type="table"}). Elrefai et al. and Al-Sarihin et al. conducted two previous studies in Jordan to assess the prevalence of DPN \[[@CR24], [@CR25]\]. Among 229 patients with diabetic foot disease, the prevalence of DPN was 89% \[[@CR24]\]. The prevalence of DPN among 202 patients with type 1 and type 2 diabetes mellitus at tertiary referral hospital was 54.4% \[[@CR25]\]. The differences in the reported prevalence rates in Jordan studies could be related to the differences in the study populations that included patients with type 1 diabetes mellitus and complicated patients with diabetic foot \[[@CR24]\].Table 5The reported prevalence of DPN in various selected studies with their diagnostic criteriaStudyCountryParticipants no. and type of DMNeuropathy diagnostic toolDPN prevalence %Current study (2016)Jordan1003 Type 2MNSI39.5%Elrefai et al. \[[@CR24]\]Jordan229 patients with diabetic footOne type of neuropathy: (presence of pain, abnormal ankle reflex, abnormal quantitative sensory testing)89%Al Sarihin et al. \[[@CR25]\]Jordan86 Type 1\
116 Type 2MNSI58.1%\
51.7%Al Mahroos et al. \[[@CR35]\]Bahrain1477 Type 2At least two abnormal tests: Neuropathy Symptom Score (NSS)\
Vibration Perception Threshold (VPT)\
Neuropathy Disability Score (NDS)36.6%Al Geffari et al. \[[@CR20]\]Saudi Arabia242 Type 2Abnormal two combined tests: (MNSI, Monofilament, vibration sensation, ankle reflex)38.79%Al-Kaabi et al. \[[@CR22]\]United Arab Emirates394 Type 2MNSI25.6%Pop-Busui et al. \[[@CR26]\]USA2368 Type2 With CADMNSI51%Liu et al. \[[@CR27]\]China1197 Type 2Pressure sensation abnormality using 10-g monofilament and impaired vibration perception using tunning fork17%Tabatabaei-Malazy et al. \[[@CR21]\]Iran124 patientsUK questionnaire\
MNSI\
Neuropathy Disability Score (NDS)\
Semmes Weinstein Monofilament (SWM)54%\
31.9%\
38.1%\
31.7%Won et al. \[[@CR29]\]Korea4000 Type 2MNSI and 10-g monofilament33.5%Katulanda et al. \[[@CR28]\]Sri Lanka528 Type2\
191 New DMDiabetic-Neuropathy-Symptom score (DNS)DNS score: 48.1%337 knownToronto-Clinical-Scoring-System (TCSS) and DNSTCSS: 24%Bansal et al. \[[@CR23]\]India1637 new Type 2One abnormal test: (10-g monofilament, pinprick sensation and ankle reflex)9.2%396 known Type 233.7%Kostev et al. \[[@CR51]\]GermanyNew Type 2 45,633Physician diagnosis or5.7%UK14,205ICD code (E11.4)2.4%

Pop-Busui et al. reported a higher prevalence among type 2 diabetic patients with angiographically documented CAD, which was 51% \[[@CR26]\]. While the prevalence of DPN among Chinese patients newly diagnosed to have diabetes without cerebrovascular disease and foot ulcers using monofilament and tuning fork was 17% \[[@CR27]\]. The discrepancy could be related to the inter subject variability in signs and symptoms of DPN and the differences in the sample selected and methods used to screen DPN \[[@CR5]\].

Our data revealed that the likelihood of DPN was higher among patients with diabetic retinopathy (OR = 2.26, 95% CI: 1.5--1.3, *p* \< *0.001*). Previous studies clearly demonstrated that diabetic patients having other microvascular and macrovascular complications were more likely to have DPN \[[@CR22], [@CR28]--[@CR30]\]. This finding can be attributed to common pathogenic mechanisms as the toxic effect of hyperglycemia in the form of increasing thickness of endo-neural micro-vessels, accumulation of advanced glycation end products (AGEs), activation of the polyol pathway and oxidative stress \[[@CR5], [@CR31]\]. In the same context, our data showed that the odds ratio for DPN in patients with cardiovascular disease was 1.43 (CI: 1.02--2.01, *p* = 0.037). DPN is a known independent predictor of all and diabetes related mortality, and coronary artery disease is the leading cause of mortality in patients with DPN \[[@CR32], [@CR33]\]. Moreover, the risk of diabetic neuropathy was doubled in patients with cardiovascular disease independent of cardiovascular risk factors \[[@CR30]\].

Among our study participants, the duration of diabetes was the strongest correlate of DPN (OR = 16.98, 95% CI: 10.19--28.28, *p* \< *0.001*) for those who were having diabetes for ≥ 12 years and (OR = 5.25, 95% CI: 3.29--8.36, *p* \< *0.001*) for those who were having diabetes for 5--11 years. This strong positive correlation was clearly demonstrated in several previous studies \[[@CR22], [@CR23], [@CR25]--[@CR30], [@CR34]\].

In agreement with other reports, our data showed that patients with dyslipidemia were 2.23 times more likely to have DPN \[[@CR28]--[@CR30], [@CR34], [@CR35]\]. Current evidence supports the theory that metabolic syndrome and obesity are risk factors for DPN. The proposed mechanisms for nerve damage include extracellular protein glycation, fat deposition, oxidative stress, mitochondrial dysfunction and activation of counter-regulatory signaling pathways leading to chronic metabolic inflammation \[[@CR36], [@CR37]\]. Moreover, elevated triglycerides may serve as a blood marker for impairment of Schwann cell lipid metabolism and the pathological changes in the myelin structure of the nerve in cases of DPN \[[@CR38]\]. Although no strong evidence for clear association between statin therapy and neuropathy is existing, still statin use could be another confounder for DPN among our study participants \[[@CR36], [@CR39], [@CR40]\]. Statins usually interfere with cholesterol synthesis through inhibition of HMG-CoA reductase, which may alter nerve membrane function. Also, co-inhibit the synthesis of the key mitochondrial respiratory chain enzyme, ubiquinone, which may disturb neuron energy utilization and thereby induce neuropathy \[[@CR40]\].

Our data showed that in comparison to patients who were physically inactive, those with not regular physical activity were less likely to have DPN (OR = 0.515, 95%CI: 0.35--0.75, *p* = 0.001). Contrary to our finding, physical inactivity was not a significant predictor of DPN in patients with DM in Sri Lanka \[[@CR28]\]. This finding highlights the importance of physical activity in the prevention of DPN and adds more evidence to already existing data that links the lack of physical activity with DPN \[[@CR22], [@CR41], [@CR42]\]. Physical activity will influence some of the underlying mechanisms of DPN in the form of microvascular dilatation, attenuation of oxidative stress and release of neurotrophic mediators in addition to its well-established role as inflammatory modulator and insulin sensitizer \[[@CR41]--[@CR43]\].

Although the prevalence of microvascular diabetic complications is strongly related to the degree of glycemic control, multivariate logistic regression analysis was unable to elicit an association between DPN and HbA1c level in the current study. Several studies evaluated the effect of glycemic control on neuropathy among patients with type 1, type 2 DM. Intensive glycemic control significantly reduced the development of both confirmed and definitive clinical neuropathy, and the benefits of prior intensive glycemic control for neuropathy were sustained in patients with type 1 DM \[[@CR44]--[@CR46]\]. While in type 2 diabetes this effect was less conclusive \[[@CR47], [@CR48]\]. The development of diabetic neuropathy is associated with a number of modifiable and non-modifiable risk factors as hypertension, dyslipidemia, insulin resistance, obesity, cigarette smoking and alcohol consumption in addition to the degree of hyperglycemia \[[@CR21]--[@CR23], [@CR25]--[@CR30], [@CR37], [@CR49]\]. The lack of association between DPN and HbA1c in the current study could be explained by the confounding effect of duration of diabetes where the intensity of glycemic control is affected by the duration of diabetes \[[@CR29]\]. Moreover, the anti-hyperglycemic medications could play a role in attenuation of the impact of glycemic control on the development and progression of diabetic neuropathy \[[@CR29]\]. In the meantime, our finding does not mean that proper glycemic control has no influence on the development of chronic DM complications as neuropathy.

Another finding in our study is the trend towards DPN protection in patients using oral hypoglycemic agents (OHA) as opposed to those using insulin therapy (OR = 0.639, 95%CI: 0.44--0.29, *p* = 0.016). This finding might be explained by the confounding effect of duration of diabetes as those who were on OHA had shorter duration of diabetes. The mean duration of DM for patients on OHA and insulin was 5.8 and 13.5 years, respectively. Furthermore, patients using insulin are already having more severe and advanced form of type 2 DM. In this study, 48.3, 27.3, 14.9 and 58% of patients receiving insulin were having CVD, retinopathy, nephropathy and neuropathy, respectively compared to 29, 12.5, 4.4 and 22.8% in patients using OHA (*p* \< *0.001*). Pop-Busui et al. demonstrated that the 4-year cumulative incidence rate of DPN was significantly lower in patients using insulin sensitizing therapy (metformin and thiazolidinediones) than those using insulin providing therapy (sulfonylurea and insulin) (*p* = 0.020) \[[@CR50]\]. Also, Kestev et al. had shown that insulin use was one of the strongest risk factors for DPN among newly diagnosed diabetics in Germany and UK \[[@CR51]\]. Metformin that was used by 85.4% of our study participants has anti-inflammatory and a direct neuroprotective effect via inhibition of oxidative stress related apoptosis in primary neurons \[[@CR28], [@CR52], [@CR53]\]. Exogenous insulin use in type 2 DM might reflect an advanced stage in the natural history of diabetes and could be associated with DPN by exacerbation of obesity, fluid retention, hypertension and hyperlipidemia \[[@CR28], [@CR29], [@CR51], [@CR54]\].

Our study is a clinic-based with large sample size, so our results may be applicable to patients receiving care in the community. The use of sensitive, highly predictive and inexpensive screening tool as MNSI to determine the prevalence of DPN will enhance the validity of the current study results. However, MNSI will assess only a large-fiber neuropathy but will not adequately assess small-fiber neuropathy, an important component of DPN. Other limitations are a cross sectional design, which could not evaluate the long-term effects of risk factors on the development of DPN as glycemic control. Further, the lack of inquiry about smoking, alcohol status and the use of medications affecting peripheral neuropathy and causality determination for neuropathy as B12 and folic acid deficiency are another limiting factors that could lead to overestimation of DPN prevalence.

Our data highlighted the need for intensive programs targeting at early detection of DPN and prompt implementation of health education in patients with dyslipidemia, cardiovascular disease, retinopathy and patients with long-standing diabetes. Moreover, initial measures to prevent DPN in the form of implementation of lifestyle and behavioral changes such as healthy eating patterns and exercise should be adopted to prevent the development and delay the progression of such a debilitating complication. Nevertheless, we need to keep in mind that action to stop diabetes epidemic is the best solution for preventing its complications.

Conclusion {#Sec8}
==========

Diabetic peripheral neuropathy is highly prevalent among Jordanian patients with T2DM. Early detection and appropriate intervention are mandatory among patients with long standing DM, dyslipidemia, diabetic retinopathy, cardiovascular disease, and unemployment.
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